Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2000
11/23/2000CA2372044A1 Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
11/23/2000CA2370066A1 Thiazolopyrimidines useful as tnf.alpha. inhibitors
11/23/2000CA2368620A1 Genetic modification of male germ cells for generation of transgenic species and genetic therapies
11/22/2000EP1054007A2 Method for the preparation of (+/-)-calanolide A
11/22/2000EP1054004A1 Novel pyrimidine-5-carboxamide derivatives
11/22/2000EP1053750A1 Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
11/22/2000EP1053351A1 Novel molecules of the tnf receptor superfamily and uses therefor
11/22/2000EP1053343A2 Targeting of genetic vaccine vectors
11/22/2000EP1053332A1 Protein
11/22/2000EP1053323A2 Human receptor proteins
11/22/2000EP1053321A1 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
11/22/2000EP1053316A1 Nucleic acids provided for modulating cellular activation
11/22/2000EP1053312A2 Optimization of immunomodulatory properties of genetic vaccines
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053301A1 A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
11/22/2000EP1053255A1 THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
11/22/2000EP1053254A2 COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT
11/22/2000EP1053251A1 The aiolos gene
11/22/2000EP1053240A1 Glucocorticoid-selective antiinflammatory agents
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053021A1 Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
11/22/2000EP1053018A2 DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES
11/22/2000EP1053017A2 Vaccines comprising interleukin-12 and herpes simplex viral antigen
11/22/2000EP1053013A1 Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
11/22/2000EP1053006A1 Costimulatory blockade and mixed chimerism in transplantation
11/22/2000EP1052992A1 Cyclic amine modulators of chemokine receptor activity
11/22/2000EP0725637B1 Parenteral busulfan for treatment of malignant disease
11/22/2000EP0701443B2 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
11/22/2000EP0669936B1 Mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace
11/22/2000EP0604631B1 Use of envelopes of bacteria of the order of Beggiatoales or of the genus Vitreoscilla as an active ingredient of a medicament for stimulating non-specific immunity
11/22/2000CN1274344A Novel vitamin D analogues
11/22/2000CN1274290A Vaccination by topical application of genetic vectors
11/22/2000CN1273967A Novel substituted dimeric compounds, its preparing process and medicinal compsns. containing same
11/22/2000CN1058724C Use of steroid compound for preparing medicaments
11/21/2000US6150557 Compounds
11/21/2000US6150539 Triptolide prodrugs having high aqueous solubility
11/21/2000US6150530 Amidation of amine with acid
11/21/2000US6150413 Treatment of dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as mammalian skin and hair conditions; 4-(4-(biphenyl-2-yl)but-3-en-1-ynyl)benzoic acid, for example
11/21/2000US6150397 5-aroylnaphthalene derivatives as anti-inflammatory agents
11/21/2000US6150373 Bicyclic nitrogen heterocycles
11/21/2000US6150340 RNA-dependent amidotransferase from Staphylococcus aureus
11/21/2000US6150326 Means for treating autoimmune diseases and method for the treatment thereof
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000US6150099 Detecting modulators of transcription factors; incubating transcription factor and modulator in solution, monitor the level of gene expression
11/21/2000US6149922 Vaccine adjuvant and vaccine
11/21/2000US6149920 Vaccine for immunization, prophylaxis or treatment of a vertebrate at risk of or suffering from brucellosis, wherein said vaccine comprises an attenuated or avirulent strain of an otherwise pathogenic bacteria of the genus brucella
11/21/2000US6149906 Activation of t-lymphocytes and induction of antigen-specific immune responses; preventing, treating various diseases ( viral, bacterial, fungal), botulism toxin, poison ivy, poison sumac
11/16/2000WO2000068383A2 Family of immunoregulators designated leukocyte immunoglobulin-like receptors (lir)
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068246A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068223A1 Ureas and their use as cell adhesion modulators
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068188A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067801A2 Prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067793A1 Death domain containing receptor 4
11/16/2000WO2000067791A1 Ccr4 antagonists in sepsis
11/16/2000WO2000067790A1 Method for treating tnf-receptor type-2-induced diseases
11/16/2000WO2000067788A2 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000WO2000067785A2 Staphyloccocus aureus antigen-containing whole cell vaccine
11/16/2000WO2000067784A1 Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof
11/16/2000WO2000067777A1 A method of prophylaxis and treatment and agents useful therefor
11/16/2000WO2000067773A2 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
11/16/2000WO2000067761A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000067700A2 Recombinant vaccine against botulinum neurotoxin
11/16/2000WO2000067697A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000WO2000067626A2 Oat extracts: refining, compositions and methods of use
11/16/2000WO2000053633A3 Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000042168A3 Bifidobacterium in the treatment of inflammatory disease
11/16/2000WO2000037639A3 Lymphocytic membrane proteins
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000023466A3 Human rna binding proteins
11/16/2000WO2000009103A3 N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders
11/16/2000DE19922407A1 Preparing medicament for treating viral infections, liver diseases or cancer, comprising recombinant parapoxvirus targeted towards specific organs, cells or tissues
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000DE19919149A1 Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere Of interferon alpha-2 derived peptide homodimers and peptide heterodimers
11/16/2000DE19919148A1 Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere Interleukin 12 derived peptide homodimers and peptide heterodimers
11/16/2000CA2374237A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000CA2373851A1 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373256A1 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000CA2373079A1 Substituted benzolactam compounds
11/16/2000CA2373063A1 Death domain containing receptor 4
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2371279A1 Recombinant vaccine against botulinum neurotoxin
11/16/2000CA2371193A1 Family of immunoregulators designated leukocyte immunoglobulin-like receptors (lir)
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000CA2368831A1 Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/15/2000EP1052285A2 Method of inducing an antigen-specific anticytotoxic cell
11/15/2000EP1052254A1 Nitrogenous heterocyclic derivatives and medicine thereof
11/15/2000EP1052238A1 Novel tricyclic compound
11/15/2000EP1051521A2 Method of screening therapeutic agents
1 ... 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 ... 1172